Patent ID: 11970712
Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An in vitro method for differentiating pluripotent stem cells, comprising exposing a plurality of pluripotent stem cells to at least one inhibitor of TGFβ/Activin-Nodal signaling, at least one inhibitor of bone morphogenetic protein (BMP) signaling,
exposing the cells to at least one activator of Sonic hedgehog (SHH) signaling and at least one inhibitor of glycogen synthase kinase 3β (GSK3β) signaling that activates wingless (Wnt) signaling, wherein the at least one activator of SHH signaling is selected from the group consisting of a Smoothened agonist (SAG), a modified N-terminal SHH, and a SHH protein comprising a N-terminal fragment and a C-terminal fragment, wherein the cells are exposed to the at least one inhibitor of GSK3β signaling three (3) days from the initial exposure of the cells to the at least one inhibitor of TGFβ/Activin-Nodal signaling and the at least one inhibitor of BMP signaling to obtain a cell population comprising at least about 10% differentiated cells expressing both forkhead box protein A2 (FOXA2) and LEVI homeobox transcription factor 1 alpha (LMX1A).